In a report released today, Matt Hewitt from Craig-Hallum reiterated a Buy rating on Apyx Medical. The company’s shares closed yesterday at $3.40.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hewitt covers the Healthcare sector, focusing on stocks such as Repligen, MaxCyte, and Schrodinger. According to TipRanks, Hewitt has an average return of 0.8% and a 43.43% success rate on recommended stocks.
In addition to Craig-Hallum, Apyx Medical also received a Buy from Lucid Capital’s Alex Fuhrman in a report issued on October 6. However, today, Citizens JMP reiterated a Hold rating on Apyx Medical (NASDAQ: APYX).
The company has a one-year high of $3.49 and a one-year low of $0.76. Currently, Apyx Medical has an average volume of 100.2K.
Read More on APYX:
Disclaimer & DisclosureReport an Issue
- Hold Rating for Apyx Medical Amid Promising Ayon System and Challenging Market Conditions
- Apyx Medical submits FDA 510k to U.S. FDA for label expansion of AYON
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- Apyx Medical’s Renuvion APR System: Promising Results in Facelift Surgery Study
/Technology%20abstract%20by%20TU%20IS%20via%20iStock.jpg)
/Quantum%20Computing/A%20concept%20image%20with%20a%20brain%20on%20top%20of%20a%20blue%20circuit%20board_%20Image%20by%20Gorodenkoff%20via%20Shutterstock_.jpg)